The risk of CAUTI increases with the number of days of catheterization and if the patients´s immune system is weak. Groups at risk of CAUTI  include the critically ill and patients with urological  obstruction ,malignancies and neurological diseases.

                        BIP Foley Catheter has been shown to reduce CAUTI in a cost effective way. Several health economic evaluations have been conducted in Europe and USA. In one of these, a large, prospective, randomized study of almost 28 000 patients, Bactiguard coated catheters were shown to offer significant annual cost savings when considering the excess cost of CAUTI. In another 2-year prospective surveillance study of 10 patient care units, the introduction of a Bactiguard coated urinary catheter was associated with a significant decline in CAUTI and led to reduced costs. The costs savings were present in a wide variety of reimbursement systems^.

       Bactiguard coated products have been used in a large number of clinical studies and evaluations (1986–2015) involving over 100,000 patients. In peer-reviewed studies looking specific on the  reduction of  CAUTI. In another 2-year prospective surveillance study of 10 patient care units, the introduction of a Bactiguard coated urinary catheter was associated with a significant decline in CAUTI and led to reduced costs.

       The costs savings were present in a wide variety of reimbursement at the incidence of symptomatic CAUTIs in patients with >2 days of catheterization (in line with current standards), the weighted average reduction of infection was 35%. In certain studies a much larger reduction, of up to 70%, was observed. In addition to that use of  Bactriguard coated catheter demonstration shown decreased bacterial adhesion ,which in turn prevents biofilm formation and subsequent infection.